Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24087960 | 1.00 | FDPS (0.36) | FDPSLMNA | |
| SCHEMBL24087820 | 0.98 | FDPS (0.35) | FDPSLMNA | |
| SCHEMBL22000500 | 0.95 | FDPS (0.32) | FDPS | |
| SCHEMBL21164154 | 0.93 | FDPS (0.34) | FDPS | |
| SCHEMBL18559601 | 0.87 | OPRM1 (0.34) | FDPS | |
| SCHEMBL23219733 | 0.87 | FDPS (0.33) | FDPS | |
| SCHEMBL21370288 | 0.87 | OPRM1 (0.34) | FDPS | |
| SCHEMBL25812965 | 0.84 | FDPS (0.31) | FDPS | |
| SCHEMBL21160752 | 0.83 | OPRM1 (0.35) | FDPS | |
| SCHEMBL18559568 | 0.83 | OPRM1 (0.35) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10660877-B2 | Pyridyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20190262311-A1 | PYRIDYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-29 | — | — | US | disclosed |
| US-10316022-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-9988386-B2 | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof | Kata Pharmaceuticals, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | FDPS 2788/4885LMNA 1725/4885 |
| US-10316022-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | FDPS 2591/4885LMNA 2477/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | FDPS 2591/4885LMNA 2477/4885 |
| US-20190262311-A1 | PYRIDYL SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR9, TLR1 | FDPS 2401/4885LMNA 2766/4885 |
| US-10660877-B2 | Pyridyl substituted indole compounds | TLR7, TLR9, TLR1 | FDPS 2401/4885LMNA 2766/4885 |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | EP300, HDAC3, HDAC1 | FDPS 3281/4885LMNA 1239/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | FDPS 2591/4885LMNA 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.